BR0010808A - Composições farmacêuticas e usos - Google Patents

Composições farmacêuticas e usos

Info

Publication number
BR0010808A
BR0010808A BR0010808-1A BR0010808A BR0010808A BR 0010808 A BR0010808 A BR 0010808A BR 0010808 A BR0010808 A BR 0010808A BR 0010808 A BR0010808 A BR 0010808A
Authority
BR
Brazil
Prior art keywords
patient
pharmaceutical compositions
treatment
bisphosphonate
angiogenesis
Prior art date
Application number
BR0010808-1A
Other languages
English (en)
Portuguese (pt)
Inventor
Tetsuji Okuno
Jonathan Green
Jeanette Marjorie Wood
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=26315578&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=BR0010808(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from GBGB9911926.5A external-priority patent/GB9911926D0/en
Priority claimed from GBGB9925131.6A external-priority patent/GB9925131D0/en
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of BR0010808A publication Critical patent/BR0010808A/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/662—Phosphorus acids or esters thereof having P—C bonds, e.g. foscarnet, trichlorfon
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/662—Phosphorus acids or esters thereof having P—C bonds, e.g. foscarnet, trichlorfon
    • A61K31/663—Compounds having two or more phosphorus acid groups or esters thereof, e.g. clodronic acid, pamidronic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Rheumatology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Pain & Pain Management (AREA)
  • Immunology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Vascular Medicine (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
BR0010808-1A 1999-05-21 2000-05-19 Composições farmacêuticas e usos BR0010808A (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GBGB9911926.5A GB9911926D0 (en) 1999-05-21 1999-05-21 Organic compounds
GBGB9925131.6A GB9925131D0 (en) 1999-10-22 1999-10-22 Organic compounds
PCT/EP2000/004562 WO2000071104A2 (en) 1999-05-21 2000-05-19 Use of bisphosphonic acids for treating angiogenesis

Publications (1)

Publication Number Publication Date
BR0010808A true BR0010808A (pt) 2002-08-27

Family

ID=26315578

Family Applications (1)

Application Number Title Priority Date Filing Date
BR0010808-1A BR0010808A (pt) 1999-05-21 2000-05-19 Composições farmacêuticas e usos

Country Status (21)

Country Link
US (2) US20020142996A1 (https=)
EP (1) EP1178810B8 (https=)
JP (1) JP2003500352A (https=)
KR (1) KR100763064B1 (https=)
CN (1) CN1202828C (https=)
AT (1) ATE293450T1 (https=)
AU (1) AU775079B2 (https=)
BR (1) BR0010808A (https=)
CA (1) CA2374049A1 (https=)
DE (1) DE60019580T2 (https=)
DK (1) DK1178810T3 (https=)
ES (1) ES2240106T3 (https=)
HU (1) HUP0201329A3 (https=)
IL (2) IL146520A0 (https=)
NO (1) NO322212B1 (https=)
NZ (1) NZ515541A (https=)
PL (1) PL351674A1 (https=)
PT (1) PT1178810E (https=)
SK (1) SK16682001A3 (https=)
TW (1) TWI224504B (https=)
WO (1) WO2000071104A2 (https=)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SI1296689T1 (sl) * 2000-06-20 2006-08-31 Novartis Ag Nacin dajanja pacientu bisfosfonatov
ES2394211T3 (es) * 2000-06-20 2013-01-23 Novartis Ag Procedimiento de administración de bifosfonatos
ATE496624T1 (de) * 2001-02-06 2011-02-15 Sydney Children S Hospitals Network Randwick And Westmead Incorporating The Royal Alexandra Hospital Arzneimittel zur behandlung von osteonekrose und zur versorgung von patienten mit risiko für die entstehung von osteonekrose
CA2443625A1 (en) * 2001-05-02 2002-11-07 Novartis Ag Use of bisphosphonates in the treatment of bone metastasis associated with prostate cancer
EP1406910B1 (fr) * 2001-07-16 2010-01-13 Universite Paris 13 Procedes de preparation de derives de bisphosphonates
TWI315982B (en) * 2001-07-19 2009-10-21 Novartis Ag Combinations comprising epothilones and pharmaceutical uses thereof
CA2478317A1 (en) * 2002-03-04 2003-09-18 Medimmune, Inc. Methods of preventing or treating disorders by administering an integrin .alpha.v.beta.3 antagonist in combination with an hmg-coa reductase inhibitor or a bisphosphonate
KR20060058151A (ko) 2002-05-10 2006-05-29 에프. 호프만-라 로슈 아게 골다공증 치료 및 예방용 비스포스폰산
DE60233576D1 (de) * 2002-12-02 2009-10-15 Innate Pharma Interleukin-2 und Gamma Delta T Zellaktivator enthaltende Zusammensetzungen und deren Verwendungen
TW200510436A (en) * 2003-07-21 2005-03-16 Novartis Ag Combinations of a cathepsin k inhibitor and a bisphosphonate in the treatment of bone metastasis, tumor growth and tumor-induced bone loss
DE602005003557D1 (de) † 2004-02-26 2008-01-10 Zentiva As Amorphe formen von of risedronat-mononatrium
EP1713489B1 (en) * 2004-08-23 2011-01-19 Teva Pharmaceutical Industries Ltd Crystalline form of ibandronate sodium and processes for preparation thereof
US7914810B2 (en) * 2005-05-06 2011-03-29 Synthes Usa, Llc Methods for the in situ treatment of bone cancer
PE20070360A1 (es) * 2005-09-01 2007-04-19 Novartis Ag Composiciones de liposomas
US20070218116A1 (en) * 2006-03-14 2007-09-20 Schwendener Reto A Compositions and methods for the treatment of tumors and tumor metastases
US20090215729A1 (en) * 2008-02-19 2009-08-27 Johnson Erin M Microparticle compositions to modify cancer promoting cells
US20160016982A1 (en) 2009-07-31 2016-01-21 Thar Pharmaceuticals, Inc. Crystallization method and bioavailability
DK2459176T3 (en) 2009-07-31 2017-12-04 Gruenenthal Gmbh Crystallization process and bioavailability
US9169279B2 (en) 2009-07-31 2015-10-27 Thar Pharmaceuticals, Inc. Crystallization method and bioavailability
US9340565B2 (en) 2010-11-24 2016-05-17 Thar Pharmaceuticals, Inc. Crystalline forms
WO2015018659A1 (en) * 2013-08-05 2015-02-12 Vib Vzw Glutamine synthetase inhibitors for inhibition of pathological angiogenesis
US10195218B2 (en) 2016-05-31 2019-02-05 Grunenthal Gmbh Crystallization method and bioavailability

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4067971A (en) * 1976-05-13 1978-01-10 The Procter & Gamble Company Therapeutic composition
DE3425812A1 (de) * 1984-07-13 1986-01-16 Deutsches Krebsforschungszentrum, 6900 Heidelberg Neue 1-hydroxy-1,1-diphosphonsaeureverbindungen, verfahren zu ihrer herstellung und pharmakologische zubereitungen, insbesondere zur behandlung von knochentumoren
IT1187828B (it) * 1985-05-24 1987-12-23 Gentili Ist Spa Composizione farmaceutica a base di difosfonati per il trattamento dell aretrosi
DE3623397A1 (de) * 1986-07-11 1988-01-14 Boehringer Mannheim Gmbh Neue diphosphonsaeurederivate, verfahren zu deren herstellung und diese verbindungen enthaltende arzneimittel
GB8618259D0 (en) * 1986-07-25 1986-09-03 Leo Pharm Prod Ltd Pharmaceutical compositions
US5116864A (en) * 1991-04-09 1992-05-26 Indiana University Foundation Method for preventing restenosis following reconfiguration of body vessels
US5358941A (en) * 1992-12-02 1994-10-25 Merck & Co., Inc. Dry mix formulation for bisphosphonic acids with lactose
TW390813B (en) * 1994-04-29 2000-05-21 Merck & Co Inc Wet granulation formulation for bisphosphonic acids
SE9402001D0 (sv) * 1994-06-09 1994-06-09 Leiras Oy Pyridylbisphosphonates for use as a therapeutical agent
IT1290444B1 (it) * 1997-03-27 1998-12-03 Boehringer Mannheim Italia Coniugati di bis-fosfonati con funzionalita' alchilanti aventi attivita' antitumorale
PT1175904E (pt) * 1997-07-22 2007-04-30 Merck & Co Inc Alendronato para utilização no tratamento da osteoporose
US5994329A (en) * 1997-07-22 1999-11-30 Merck & Co., Inc. Method for inhibiting bone resorption
US6048861A (en) * 1997-12-17 2000-04-11 Merck & Co., Inc. Integrin receptor antagonists
EP0998934A4 (en) * 1997-12-25 2005-09-14 Toray Industries REMEDIES AGAINST INTRAMEDULLARY DISEASES
US6416964B2 (en) * 1998-01-29 2002-07-09 Merck & Co., Inc. Methods of identifying modulators of kinases responsive to stress
WO1999038998A1 (en) * 1998-01-29 1999-08-05 Merck & Co., Inc. Methods of identifying modulators of kinases responsive to stress
IL125336A0 (en) * 1998-07-14 1999-03-12 Yissum Res Dev Co Compositions for inhibition and treatment of restinosis
AU1525700A (en) * 1998-11-19 2000-06-05 Board Of Trustees Of The University Of Arkansas, The Increasing bone strength with selected bisphosphonates
US6426367B1 (en) * 1999-09-09 2002-07-30 Efa Sciences Llc Methods for selectively occluding blood supplies to neoplasias
US6677320B2 (en) * 2000-01-20 2004-01-13 Hoffmann-La Roches Inc. Parenteral bisphosphonate composition with improved local tolerance

Also Published As

Publication number Publication date
ES2240106T3 (es) 2005-10-16
IL146520A (en) 2006-09-05
EP1178810B1 (en) 2005-04-20
EP1178810B8 (en) 2005-07-27
DK1178810T3 (da) 2005-07-11
US20020142996A1 (en) 2002-10-03
NO20015638L (no) 2002-01-15
PL351674A1 (en) 2003-05-19
WO2000071104A2 (en) 2000-11-30
CN1202828C (zh) 2005-05-25
KR20010113830A (ko) 2001-12-28
HUP0201329A2 (en) 2002-08-28
DE60019580T2 (de) 2006-03-09
CN1384749A (zh) 2002-12-11
AU5214100A (en) 2000-12-12
WO2000071104A3 (en) 2001-07-19
ATE293450T1 (de) 2005-05-15
CA2374049A1 (en) 2000-11-30
SK16682001A3 (sk) 2002-04-04
KR100763064B1 (ko) 2007-10-04
NO322212B1 (no) 2006-08-28
JP2003500352A (ja) 2003-01-07
NZ515541A (en) 2003-03-28
PT1178810E (pt) 2005-08-31
DE60019580D1 (de) 2005-05-25
NO20015638D0 (no) 2001-11-19
AU775079B2 (en) 2004-07-15
IL146520A0 (en) 2002-07-25
US20040176327A1 (en) 2004-09-09
TWI224504B (en) 2004-12-01
HUP0201329A3 (en) 2005-02-28
EP1178810A2 (en) 2002-02-13

Similar Documents

Publication Publication Date Title
BR0010808A (pt) Composições farmacêuticas e usos
BR0209365A (pt) Usos farmacêuticos de bisfosfonatos
BR0115696A (pt) Uso de bisfosfonatos para tratamento de dor
DE69713526D1 (de) Lösliche prodrugs von paclitaxel
BG100911A (en) Biophosphonic acids-sontaining wet-granulated form
BR0110913A (pt) Método de administrar um bisfosfonato
BR0006301A (pt) Macrólidos antibacterianos e pró-cinéticos
FR2684381B1 (fr) Composes presentant une liaison amide phosphorique ou une liaison phosphate d'enol pour leur application en tant que substance therapeutiquement active.
BR0017329A (pt) Formulção farmacêutica de um medicamento, uso de melatonina na fabricação de um medicamento, e, método para prevenção ou tratamento de sintomas de discinesia tardia em um paciente usanto tal medicamento
BR0014233A (pt) Conjugados de 4-benzilaminoquinolina com ácido galênico e seus heteroanálogos, processos para a sua preparação, medicamentos contendo estes compostos e sua aplicação
BR0011845A (pt) Complexo farmacêutico
BR0213410A (pt) Usos farmacêuticos de bisfosfonatos
ES2152865A1 (es) Utilizacion de bisfosfonatos en la preparacion de composiciones farmaceuticas para uso intramuscular.
EA200100080A1 (ru) Лекарственные средства, содержащие бисфосфоновые кислоты и их производные, предназначенные для профилактики и лечения аутоиммунных заболеваний и аллергий
Bando et al. Release of nitrogen-containing bisphosphonates (NBPs) from hydroxyapatite by non-NBPs and by pyrophosphate
BR0106601A (pt) Composição farmacêutica contendo bisfosfonato para o tratamento de doenças relacionadas ao metabolismo de cálcio e/ou fosfato, seu uso na preparação de medicamento para o tratamento de doenças relacionadas ao metabolismo de cálcio e/ou fosfato, método de tratamento de doenças relacionadas ao metabolismo de cálcio e/ou fosfato
BR0016646A (pt) Método para tratar um paciente que sofre de dor, e, composição farmacêutica
BR0307021A (pt) Uso de alquilfosfocolinas no tratamento preventivo de doenças de protozoários
BR9812466A (pt) Uso de ifn-alfa e amantadina para o tratamento da hepatite c crÈnica
TH51552A (th) การใช้กรดบิสฟอสโฟนิคสำหรับการบำบัดแอนจิโอจีนีซิส
BR9714774A (pt) Pró-drogas solúveis de paclitaxel
AR017240A2 (es) COMPOSICIONES DE ÁCIDO ALENDRoNICO , SUS SALES O ESTERES
AR004157A1 (es) Sal del tipo 2'-onio de paclitaxel soluble en agua, metodo de preparacion y uso de la misma y forma de dosificacion que la contiene.
AR013500A1 (es) Uso de acido alendronico o una sal farmaceuticamente aceptable del mismo o una mezcal de los mismos para la manufactura de un medicamento

Legal Events

Date Code Title Description
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B09B Patent application refused [chapter 9.2 patent gazette]

Free format text: INDEFIRO O PEDIDO DE ACORDO COM ARTIGOS 8O, 10( VIII ), 11, 24 E 25 DA LPI.

B09B Patent application refused [chapter 9.2 patent gazette]

Free format text: MANTIDO O INDEFERIMENTO UMA VEZ QUE NAO FOI APRESENTADO RECURSO DENTRO DO PRAZO LEGAL.